... treatment strategy for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative BC since this subtype of BC depends on signaling through the estrogen receptor (ER). ET combined with targeted therapy has been demonstrated to enhance treatment effects. Alterations in the cyclin...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. St. Gallen Consensus 2021 Early breast cancer (Neo)adjuvant systemic treatment Targeted therapy The German experts point out that each of the two specified...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Metastatic breast cancer Genomic testing Genetic testing Targeted therapy Review Article Breast Care 2021;16:101...

... surgery Sentinel node Axillary dissection Radiotherapy Targeted therapy The St. Gallen Consensus Conference 2019 (March 20–23) was held in Vienna, Austria, for the third time. Giuseppe Curigliano and Eric Winer chaired the panel discussion and the voting. Once again, the conference focused...

... options, dermatologic side effects are also becoming increasingly complex and more challenging for the clinician. We reviewed the most common dermatologic side effects of current anticancer therapy, including toxicity induced by chemotherapy, targeted therapy, and immunotherapy. In particular, we focus...

... systemic therapy Adjuvant treatment Endocrine therapy Chemotherapy Bisphosphonates Denosumab Breast surgery Sentinel node Axillary dissection Radiotherapy Targeted therapy The St. Gallen Consensus Conference 2017 (March 15-18) was again held in Vienna, Austria. Panel discussion and voting...

.... In the case of HER2-positive early or metastatic BC, targeted therapies are well established and remain a major focus of ongoing research. The introduction of anti-HER2 biologicals such as trastuzumab, pertuzumab, and T-DM1 has made targeted and personalized treatment possible and has clearly improved disease...

...Soumaya Labidi; Nesrine Mejri; Aymen Lagha; Nouha Daoud; Houda El Benna; Mehdi Afrit; Hamouda Boussen Summary Human epidermal growth factor receptor-2 (HER2) is amplified in 25-30% of breast cancers and is associated with aggressive disease and poorer survival. Multiple anti-HER2 targeted therapies...

...Cornelia Liedtke; Hans-Christian Kolberg Summary Systemic therapy of metastatic breast cancer may include chemotherapy, endocrine therapy, and targeted therapies (e.g., antibody-based approaches). These agents may be employed alone or in combination based on the patient's breast cancer subtype...

...Frederik Marmé; Andreas Schneeweiss Summary Triple-negative breast cancer (TNBC) is a heterogeneous disease comprised of several biologically distinct subtypes. However, treatment is currently mainly relying on chemotherapy as there are no targeted therapies specifically approved for TNBC. Despite...

...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2015 Guidelines Locoregional relapse Metastatic breast cancer Targeted therapy For the last 14 years...

... and endocrine treatment, chemotherapy, targeted therapy, as well as adjuvant bisphosphonate use. This report is not aimed to replace the official St. Gallen consensus publication - some recommendations may even be altered in the final paper - but should serve as a preliminary rapid report of this important...

...Elmar Stickeler; Tanja Fehm In 2014, modern strategies of targeted therapies in the adjuvant setting are mainly focused on anti-human epidermal growth factor receptor 2 (HER2) blockade. For the 15% of HER2-enriched tumors, 1 year of treatment with the monoclonal antibody trastuzumab is the standard...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Guidelines Locoregional relapse Metastatic breast cancer Targeted therapy For the last 13 years, the Breast...

... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Guidelines Locoregional relapse Metastatic breast cancer Targeted therapy For the last 12 years, the Breast Committee...

.... Targeted therapy St. Gallen Consensus Early breast cancer Adjuvant therapy Multigene signatures St. Gallen Consensus Frühes Mammakarzinom Adjuvante Therapie Zielgerichtete Therapie Multigensignaturen Alle zwei Jahre findet in St. Gallen (Schweiz) die internationale...

... of the 2013 international panel voting procedures with regard to loco-regional and endocrine treatment, chemotherapy, targeted therapy as well as adjuvant bisphosphonate use. This report is not aimed to replace the official St. Gallen Consensus publication, some recommendations may even be altered...

... or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Breast cancer Chemotherapy Neoadjuvant therapy Targeted therapy Breast Care Review Article · Übersichtsarbeit Breast Care 2011;6:427 433 DOI: 10.1159/000335331 Published online...

... of the 2011 international panel voting procedures with regard to locoregional and endocrine treatment, chemotherapy, targeted therapy as well as adjuvant bisphosphonate use. 29 4 2011 © 2011 S. Karger AG, Basel 2011 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part...

.... Marien, Amberg, 28Universitätsfrauenklinik Tübingen, Germany Keywords Early Breast Cancer · Endocrine treatment · Neoadjuvant therapy · Targeted therapy · Predictive and prognostic markers Schlüsselwörter Frühes Mammakarzinom · Endokrine Therapie · neoadjuvante Therapie · Zielgerichtete Therapie...